CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 113 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $350,310 | +430.8% | 23,495 | +24.1% | 0.00% | – |
| Q3 2022 | $66,000 | +106.2% | 18,932 | +76.7% | 0.00% | – |
| Q2 2022 | $32,000 | -17.9% | 10,714 | -13.5% | 0.00% | – |
| Q1 2022 | $39,000 | -22.0% | 12,391 | +7.4% | 0.00% | – |
| Q2 2021 | $50,000 | +614.3% | 11,540 | +602.4% | 0.00% | – |
| Q1 2021 | $7,000 | -93.4% | 1,643 | -91.1% | 0.00% | – |
| Q4 2020 | $106,000 | -45.1% | 18,450 | -31.0% | 0.00% | -100.0% |
| Q3 2020 | $193,000 | +2044.4% | 26,720 | +2211.4% | 0.00% | – |
| Q4 2018 | $9,000 | -80.0% | 1,156 | -66.7% | 0.00% | – |
| Q1 2018 | $45,000 | +87.5% | 3,475 | -15.4% | 0.00% | – |
| Q2 2017 | $24,000 | – | 4,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |